Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.

Baird RD, van Rossum AGJ, Oliveira M, Beelen K, Gao M, Schrier M, Mandjes IAM, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, van Tinteren H, Callari M, Beddowes E, Perez-Garcia JM, Rosing H, Platte E, Nederlof P, Schot M, de Vries Schultink A, Bernards R, Saura C, Gallagher W, Cortès J, Caldas C, Linn SC.

Clin Cancer Res. 2019 Nov 15;25(22):6598-6605. doi: 10.1158/1078-0432.CCR-19-0508. Epub 2019 Aug 22.

PMID:
31439579
2.

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).

van Rossum AGJ, Kok M, van Werkhoven E, Opdam M, Mandjes IAM, van Leeuwen-Stok AE, van Tinteren H, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, Wesseling J, Rutgers EJ, Linn SC, Oosterkamp HM; MATADOR Trialists' Group.

Eur J Cancer. 2018 Oct;102:40-48. doi: 10.1016/j.ejca.2018.07.013.

3.

Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.

van Rossum AGJ, Kok M, McCool D, Opdam M, Miltenburg NC, Mandjes IAM, van Leeuwen-Stok E, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, van Werkhoven E, Schmidt MK, Oosterkamp HM, Linn SC.

Oncotarget. 2017 Nov 27;8(69):113531-113542. doi: 10.18632/oncotarget.22697. eCollection 2017 Dec 26.

4.

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.

van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, Solbach C, Köhne CH, Thomssen C, Forstbauer H, Hoffmann G, Kohls A, Schmatloch S, Schem C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F.

Breast Cancer Res Treat. 2017 Dec;166(3):775-785. doi: 10.1007/s10549-017-4444-9. Epub 2017 Aug 18.

PMID:
28822007
5.

βTrCP interacts with the ubiquitin-dependent endocytosis motif of the GH receptor in an unconventional manner.

da Silva Almeida AC, Hocking HG, Boelens R, Strous GJ, van Rossum AG.

Biochem J. 2013 Jul 15;453(2):291-301. doi: 10.1042/BJ20121843.

PMID:
23607312
6.

Subphenotypes of mild-to-moderate COPD by factor and cluster analysis of pulmonary function, CT imaging and breathomics in a population-based survey.

Fens N, van Rossum AG, Zanen P, van Ginneken B, van Klaveren RJ, Zwinderman AH, Sterk PJ.

COPD. 2013 Jun;10(3):277-85. doi: 10.3109/15412555.2012.744388. Epub 2013 Mar 28.

PMID:
23536961
7.

βTrCP controls GH receptor degradation via two different motifs.

da Silva Almeida AC, Strous GJ, van Rossum AG.

Mol Endocrinol. 2012 Jan;26(1):165-77. doi: 10.1210/me.2011-1211. Epub 2011 Oct 27.

8.

Jak2 is a negative regulator of ubiquitin-dependent endocytosis of the growth hormone receptor.

Putters J, da Silva Almeida AC, van Kerkhof P, van Rossum AG, Gracanin A, Strous GJ.

PLoS One. 2011 Feb 9;6(2):e14676. doi: 10.1371/journal.pone.0014676.

9.

Towards understanding CRUMBS function in retinal dystrophies.

Richard M, Roepman R, Aartsen WM, van Rossum AG, den Hollander AI, Knust E, Wijnholds J, Cremers FP.

Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R235-43. Review.

PMID:
16987889
10.

Pals1/Mpp5 is required for correct localization of Crb1 at the subapical region in polarized Muller glia cells.

van Rossum AG, Aartsen WM, Meuleman J, Klooster J, Malysheva A, Versteeg I, Arsanto JP, Le Bivic A, Wijnholds J.

Hum Mol Genet. 2006 Sep 15;15(18):2659-72. Epub 2006 Aug 2.

PMID:
16885194
11.

Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.

van Rossum AG, van Bragt MP, Schuuring-Scholtes E, van der Ploeg JC, van Krieken JH, Kluin PM, Schuuring E.

BMC Cancer. 2006 Mar 14;6:58.

12.

Cortactin affects cell migration by regulating intercellular adhesion and cell spreading.

van Rossum AG, Moolenaar WH, Schuuring E.

Exp Cell Res. 2006 May 15;312(9):1658-70. Epub 2006 Mar 9.

PMID:
16527272
13.

Mpp4 recruits Psd95 and Veli3 towards the photoreceptor synapse.

Aartsen WM, Kantardzhieva A, Klooster J, van Rossum AG, van de Pavert SA, Versteeg I, Cardozo BN, Tonagel F, Beck SC, Tanimoto N, Seeliger MW, Wijnholds J.

Hum Mol Genet. 2006 Apr 15;15(8):1291-302. Epub 2006 Mar 6.

PMID:
16520334
14.
15.

Comparative genome analysis of cortactin and HS1: the significance of the F-actin binding repeat domain.

van Rossum AG, Schuuring-Scholtes E, van Buuren-van Seggelen V, Kluin PM, Schuuring E.

BMC Genomics. 2005 Feb 14;6:15.

16.

Alternative splicing of the actin binding domain of human cortactin affects cell migration.

van Rossum AG, de Graaf JH, Schuuring-Scholtes E, Kluin PM, Fan YX, Zhan X, Moolenaar WH, Schuuring E.

J Biol Chem. 2003 Nov 14;278(46):45672-9. Epub 2003 Sep 2.

17.

Characterization of mouse thrombin-activatable fibrinolysis inhibitor.

Marx PF, Wagenaar GT, Reijerkerk A, Tiekstra MJ, van Rossum AG, Gebbink MF, Meijers JC.

Thromb Haemost. 2000 Feb;83(2):297-303.

PMID:
10739389

Supplemental Content

Loading ...
Support Center